Nexalin Technology (NXL) Cash from Financing Activities (2021 - 2026)
Nexalin Technology (NXL) posted Cash from Financing Activities of $138365.0 for Q2 2026, down 81.71% on a QoQ basis from $756421.0 in Q1 2026.
Analysis
Nexalin Technology (NXL) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Cash from Financing Activities for 5 years, with the latest figure at $138365.0 in Q2 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $138365.0 in Q2 2026; TTM through Jun 2026 was $1.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.2 million, up 14.48% from the prior year.
- Cash from Financing Activities was $138365.0 for Q2 2026 at Nexalin Technology, down from $756421.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $8.5 million in Q3 2022, with the low at -$200000.0 in Q1 2023.
- Average Cash from Financing Activities over 4 years is $1.4 million, with a median of $138365.0 recorded in 2026.
- The largest YoY upside for Cash from Financing Activities was 200100.0% in 2023 against a maximum downside of 200100.0% in 2023.
- Over 4 years, Cash from Financing Activities stood at $8.5 million in 2022, then plunged by 102.35% to -$200000.0 in 2023, then soared by 361.78% to $523550.0 in 2025, then plunged by 73.57% to $138365.0 in 2026.
- The last three Cash from Financing Activities figures came in at $138365.0 (Q2 2026), $756421.0 (Q1 2026), and $523550.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | -343.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | -95.00 Mn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | -410.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | -300,000.00 |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -510.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | -607.30 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | 138,365.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 138,365.00 |
| Mar 31, 2026 | 756,421.00 |
| Dec 31, 2025 | 523,550.00 |
| Mar 31, 2023 | -200,000.00 |
| Sep 30, 2022 | 8.52 Mn |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 100.00 |
| Dec 31, 2021 | 934,443.00 |